Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 19 Neoplasm Metastasis 6 Neoplasms 4 Carcinoma, Squamous Cell 4 Squamous Cell Carcinoma of Head and Neck 3 Lung Neoplasms 3 Brain Neoplasms 3 Recurrence 2 Head and Neck Neoplasms 2 Glioblastoma 2 Carcinoma 2 Triple Negative Breast Neoplasms 1 Thrombocytosis 1 Skin Squamous Cell Cancer 1 Rare Tumor 1 Prostatic Neoplasms 1 Primary Myelofibrosis 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Penile Neoplasms 1 Pancreatic Neoplasms 1 Non-small Cell Lung Cancer Metastatic 1 NSCLC 1 Myeloproliferative Disorders 1 Myelodysplastic-Myeloproliferative Diseases 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Mouth Neoplasms 1 Lymphoma, Non-Hodgkin 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Myeloid, Chronic-Phase 1

Interventions

sintilimab 1 pyrotinib 1 palbociclib 1 niraparib 1 dacomitinib 1 aumolertinib 1 atezolizumab 1 alectinib 1 Vemurafenib 1 Imatinib Mesylate 1 Crizotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Rare Tumor × dacomitinib × Clear all

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting

Rare Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡